Form 4 for KPTI Karyopharm Therapeutics Inc.
Accepted 2023-03-02 00:00:00 ET · period of report 2023-02-28 · accession 0001209191-23-014838 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-02 | 2023-02-28 | KPTI | Paulson Richard A. | Pres, CEO, Dir | A - Grant | $0.00 | +252.0K | 856.7K | +42% | $0 | |
| 2023-03-02 | 2023-03-01 | KPTI | Paulson Richard A. | Pres, CEO, Dir | S - Sale | $3.03 | -33.0K | 823.6K | -4% | -$100.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-28 | A | A | 252,000 | $0.00 | 856,655 | D | — | — | (F1) Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024. |
| 2 | Common | Common Stock | 2023-03-01 | S | D | 33,033 | $3.03 | 823,622 | D | — | — |